Skip to content
PeptideTech
Cart

Home / Research library / SS-31

Peptides

SS-31: molecular data, studies & sources

SS-31 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C32H49N9O5
Molecular weight (MW)
639.8 g/mol
PubChem compound ID
11764719
Record title
Elamipretide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 11764719 · retrieved 2026-09-21

PubChem 2D molecular structure for SS-31, CID 11764719
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide
InChIKey
SFVLTCAESLKEHH-WKAQUBQDSA-N
SMILES
CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)N)C)O
Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

    Thompson WR, Manuel R, Abbruscato A et al. · Genetics in medicine : official journal of the American College of Medical Genetics · 2024

    PMID 38602181 · DOI: 10.1016/j.gim.2024.101138

  2. Human study · PubMed trial index

    Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

    Karaa A, Bertini E, Carelli V et al. · Neurology · 2023

    PMID 37268435 · DOI: 10.1212/WNL.0000000000207402

  3. Human study · PubMed trial index

    Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

    Karaa A, Bertini E, Carelli V et al. · Orphanet journal of rare diseases · 2024

    PMID 39574155 · DOI: 10.1186/s13023-024-03421-5

  4. Human study · PubMed trial index

    A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

    Karaa A, Haas R, Goldstein A et al. · Journal of cachexia, sarcopenia and muscle · 2020

    PMID 32096613 · DOI: 10.1002/jcsm.12559

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    Targeting mitochondrial dysfunction with elamipretide.

    Obi C, Smith AT, Hughes GJ et al. · Heart failure reviews · 2022

    PMID 35037146 · DOI: 10.1007/s10741-021-10199-2

  2. Review · secondary evidence

    Elamipretide: First Approval.

    Shirley M · Drugs · 2026

    PMID 41335372 · DOI: 10.1007/s40265-025-02269-8

SS-31 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Compare all SS-31 sizes, forms and supplier prices →

SupplierRecorded packagesExample source listing
American PeptidesUSD10mg Vial · 30mg Vial · 50mg Vial3 recorded offers10mg Vial · $70.00Checked Sep 21, 2026Supplier listing
Blank PeptidesUSD10mg Vial1 recorded offers10mg Vial · $70.00Checked Sep 21, 2026Supplier listing
US Peptide LabsUSD10mg Vial1 recorded offers10mg Vial · $60.00Checked Sep 16, 2026Supplier listing
Direct PeptidesUSD10mg Vial1 recorded offers10mg Vial · $69.00Checked Sep 16, 2026Supplier listing
Particle PeptidesEUR50mg Vial1 recorded offers50mg Vial · €194.99Checked Sep 16, 2026Supplier listing
Nuvion PeptidesCAD50mg Vial1 recorded offers50mg Vial · CA$149.99Checked Sep 21, 2026Supplier listing
PhaseOneAUD10mg Vial1 recorded offers10mg Vial · A$59.99Recorded out of stock · Checked Sep 21, 2026Supplier listing
BioStacksCAD10mg Vial1 recorded offers10mg Vial · CA$80.00Checked Sep 21, 2026Supplier listing
AllMyPeptidesGBP10mg Vial1 recorded offers10mg Vial · £28.99Checked Sep 17, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles